AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The DURGA-4 study, formally titled “A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120… Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma,” aims to show whether AstraZeneca’s new cell therapy can improve outcomes in patients whose blood cancer has come back after prior treatment. The trial targets a high-need group and could reshape later-line myeloma care if results are strong.
The main treatment tested is AZD0120, an engineered cell therapy known as CAR-T that targets two markers on myeloma cells, BCMA and CD19, to kill cancer more precisely. It is being compared against current drug combinations that use well-known myeloma agents like daratumumab, carfilzomib, pomalidomide, bortezomib, and dexamethasone.
This is a Phase 3 study where patients are randomly assigned to either AZD0120 or one of several standard drug regimens, so results should be robust and less biased. The trial is open-label, meaning both doctors and patients know which treatment is given, and the main goal is to see which option controls the cancer better and more safely.
The study was first submitted in late January 2026, marking the formal launch of a large, late-stage program in a competitive oncology space. The latest update in March 2026 confirms that recruitment is active, and while primary and final completion dates are not yet posted, investors should assume data are several years away, typical for a global Phase 3 cancer trial.
For AstraZeneca (GB:AZN), a positive update from DURGA-4 could strengthen its position in blood cancers and diversify revenue beyond its core oncology drugs, supporting a higher valuation multiple over time. Success would also add pressure on existing myeloma players such as Johnson & Johnson and Bristol Myers Squibb, while reinforcing investor interest in dual-target CAR-T platforms across the sector.
The DURGA-4 trial for AZD0120 in relapsed refractory multiple myeloma is currently ongoing with recent updates posted, and further details are available on the ClinicalTrials.gov portal.
To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.